Get started
Novartis AGNovartis AGNovartis AG

Novartis AG

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVS chart


Full chart

Key facts today

Novartis reported that its Phase III study of intrathecal onasemnogene abeparvovec successfully met its primary endpoint in children and young adults diagnosed with spinal muscular atrophy (SMA).
Analyze the impactAnalyze the impact

NVS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪195.66 B‬ USD
Dividend yield (indicated)
3.22%
Price to earnings Ratio (TTM)
11.48
Basic EPS (TTM)
8.63 USD
Net income (FY)
‪14.85 B‬ USD
Revenue (FY)
‪45.44 B‬ USD
Shares float
‪1.96 B‬
Beta (1Y)
0.38

About NOVARTIS N


Sector
Health Technology
CEO
Vasant Narasimhan
Headquarters
Basel
Website
novartis.com
Founded
1996
FIGI
BBG000LYF3S8
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NVS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVS highest yielding bonds


N
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.65%
Maturity date
Aug 14, 2050
N
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
5.98%
Maturity date
Nov 20, 2045
N
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.95%
Maturity date
Sep 21, 2042
N
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.81%
Maturity date
May 6, 2044
N
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.74%
Maturity date
Sep 18, 2054
N
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
5.29%
Maturity date
Sep 18, 2034
N
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
5.15%
Maturity date
Aug 14, 2030
N
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.98%
Maturity date
Sep 18, 2031
N
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.85%
Maturity date
Sep 18, 2029
N
US66989HAP3
NOVARTIS CAP 20/25
Yield to maturity
4.70%
Maturity date
Feb 14, 2025
N
US66989HAN8
NOVARTIS CAPITAL 17/27
Yield to maturity
4.65%
Maturity date
May 17, 2027

Explore more bonds 

Sparks


Curated watchlists where NVS is featured.

See all sparks